Verapamil

CAT: 0804-HY-14275-01Size: 50 mgDry Ice: NoHazardous: No
CAT#:0804-HY-14275-01Size:50 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Verapamil ((±) -Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].
CAS Number
[52-53-9]
Product Name Alternative
(±) -Verapamil; CP-16533-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Calcium Channel; Cytochrome P450; P-glycoprotein
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/verapamil.html
Purity
99.96
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COC1=CC=C(C(C#N)(C(C)C)CCCN(CCC2=CC=C(OC)C(OC)=C2)C)C=C1OC
Molecular Formula
C27H38N2O4
Molecular Weight
454.60
Precautions
H302, H315, H319, H335
References & Citations
[1]Gowarty JL, et al. Verapamil as a culprit of palbociclib toxicity. J Oncol Pharm Pract. 2019 Apr;25 (3) :743-746.|[2]Krikler DM. Verapamil in arrhythmia. Br J Clin Pharmacol. 1986;21 Suppl 2:183S-189S.|[3]Rehnqvist N, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) . Eur Heart J. 1996 Jan;17 (1) :76-81.|[4]Kubo Y, et al. Blood-to-Retina Transport of Fluorescence-Labeled Verapamil at the Blood-Retinal Barrier. Pharm Res. 2018 Mar 12;35 (5) :93.|[5]Zhou P, et al. Anti-arrhythmic effect of Verapamil is accompanied by preservation of cx43 protein in rat heart. PLoS One. 2013 Aug 12;8 (8) :e71567.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
CYP3
Citation 01
ACS Appl Nano Mater. 2025 Jan 21.|Adv Funct Mater. 2025 May 15.|Adv Funct Mater. 2025 May 5.|Adv Mater. 2023 Nov;35 (45) :e2211980.|Antibiotics (Basel) . 2022 Jul 26;11 (8) :1005.|Bioact Mater. 2021 Apr 21;6 (11) :4073-4082.|Biochem Biophys Res Commun. 2024 Jan 8:691:149314.|Biochem Pharmacol. 2025 Aug 12;242 (Pt 2) :117233.|Biomed Chromatogr. 2024 Aug 17:e5984.|Biomed Pharmacother. 2020 Sep;129:110506.|Biomed Pharmacother. 2024 Nov:180:117568.|Biomed Pharmacother. 2024 Oct 28:180:117603.|Biomed Res Int. 2021 May 14:2021:5565748.|BMC Cancer. 2025 Jan 7;25 (1) :24.|Br J Pharmacol. 2021 Oct;178 (20) :4155-4175.|Braz J Med Biol Res. 2024 Jul 1:57:e13357.|Cell Commun Signal. 2024 Jun 13;22 (1) :325.|Drug Metab Dispos. 2025 Sep 24.|Eur J Pharmacol. 2021 Nov 15:911:174552.|Eur J Pharmacol. 2022 Dec 5:936:175343.|Eur J Pharmacol. 2024 Apr 15:969:176431.|FEBS J. 2024 Jul;291 (14) :3249-3266.|Free Radic Biol Med. 2024 Jun 19:S0891-5849 (24) 00531-8.|Int J Mol Sci. 2024 Oct 22;25 (21) :11346.|Int J Mol Sci. 2025 Jan 6;26 (1) :412.|Interdiscip Med. 2025 Sep 1;3 (5) :e70053.|J Ethnopharmacol. 2025 Apr 14:347:119803.|J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|J Nat Med. 2025 May;79 (3) :621-638.|J Orthop Surg Res. 2024 Feb 19;19 (1) :147.|medRxiv. 2025 May 21.|Microbiol Spectr. 2024 Jan 11;12 (1) :e0251023.|Mol Pharm. 2025 Feb 3;22 (2) :733-746.|Nat Commun. 2024 Jun 19;15 (1) :5230.|Neurochem Res. 2023 May;48 (5) :1424-1437.|Pak J Pharm Sci. 2022 Mar;35 (2) :571-578.|Pak J Pharm Sci. 2022 Mar;35 (2) :587-594.|Pestic Biochem Physiol. 2022 Aug:186:105170.|Pestic Biochem Physiol. 2025 Oct 24.|Pharmacol Res Perspect. 2022 Feb;10 (1) :e00928.|Phytomedicine. 2025 Oct 21.|Research (Wash D C) . 2024 Mar 11:7:0335.|Research Square Preprint. 2020 Dec.|Research Square Preprint. 2020 Oct.|Research Square Print. 2022.|SSRN. 8 Nov 2022|Antivir Ther. 2025 Oct;30 (5) :13596535251377204.|Biochem Biophys Res Commun. 2020 Jan 15;521 (3) :596-602.|Cancer Cell Int. 2021 Feb 16;21 (1) :108.|Cancer Cell. 2017 Apr 10;31 (4) :501-515.e8. |Cancer Res Commun. 2024 Apr 9;4 (4) :1024-1040.|Cancer Sci. 2018 Apr;109 (4) :1135-1146. |Cancers (Basel) . 2021 Aug 6;13 (16) :3978.|Cell Calcium. 2020 May;87:102171.|Cell Stem Cell. 2023 Apr 6;30 (4) :378-395.e8.|Comp Biochem Physiol C Toxicol Pharmacol. 2024 Jul 20:109980.|Faculty of Pharmacy in Hradec Králové. Department of Pharmacology and Toxicology. Charles University 2019 Apr.|Food Funct. 2021 Sep 20;12 (18) :8440-8453.|Inflammopharmacology. 2023 Jun;31 (3) :1511-1527.|J Pharm Anal. 2020 Apr;10 (2) :178-186.|Mol Cell Endocrinol. 2019 Aug 20:494:110490.|Pharm Biol. 2019 Dec;57 (1) :477-484.|Phytomedicine. 2019 Mar 15:56:175-182.|PLoS Biol. 2024 Mar 25;22 (3) :e3002565.|Preprints. 2024 Jun 12.|SSRN. 2024 Jun 4.|SSRN. 2025 Jun 3.|SSRN. 2025 Oct 22.|Toxicol Appl Pharmacol. 2019 Apr 1:368:18-25.|Toxicol Res Appl. 2018, 2:239784731880115.|Toxicol Res Appl. September 25, 2018.|Université de Lausanne. 2024 Feb 7.|Xenobiotica. 2019 Dec;49 (12) :1485-1493.

Alternative Products

CatalogName
M27305-01Verapamil
MBS808013-01Verapamil HCl
TRC-V125000-500MGVerapamil Hydrochloride
A12679-500Verapamil 500mg

Popular Products